Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Jiang, Weiwei ^a   Jin, Guanghui ^a,b   Ma, Dingyuan ^a   Wang, Feng ^c   Fu, Tong ^c   Chen, Xiao ^a   Chen, Xiwen ^a   Jia, Kunzhi ^a   Marikar, Faiz M M T ^a   Hua, Zichun ^a  

^a NANJING UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARGINYLGLYCYLARGININE; CISPLATIN; RECOMBINANT PLASMINOGEN KRINGLE 5; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; NGR PEPTIDE; OLIGOPEPTIDE; PEPTIDE FRAGMENT; PLASMINOGEN; PLASMINOGEN KRINGLE 5;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOTHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LOW DRUG DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; ANIMAL; CELL MOTION; CHICK EMBRYO; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROTEIN MOTIF; TUMOR CELL LINE;

CITRUS MACROPHYLLA; MUS;

AMINO ACID MOTIFS; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHICK EMBRYO; FEMALE; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PLASMINOGEN; RECOMBINANT FUSION PROTEINS;

EID: 84861012001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037132     Document Type: Article

References (50)

1. Arap W, Pasqualini R, Ruoslahti E, (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380.
2. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, et al. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727.
3. Corti A, Curnis F, (2011) Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol 12: 1128-1134.
4. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, et al. (2000) Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18: 1185-1190.
5. van Hensbergen Y, Broxterman HJ, Elderkamp YW, Lankelma J, Beers JC, et al. (2002) A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem Pharmacol 63: 897-908.
6. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
7. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, et al. (2003) Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 63: 7400-7409.
8. Kessler T, Schwoppe C, Liersch R, Schliemann C, Hintelmann H, et al. (2008) Generation of fusion proteins for selective occlusion of tumor vessels. Curr Drug Discov Technol 5: 1-8.
9. Dreischaluck J, Schwoppe C, Spieker T, Kessler T, Tiemann K, et al. (2010) Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Int J Oncol 37: 1389-1397.
10. Schwoppe C, Kessler T, Persigehl T, Liersch R, Hintelmann H, et al. (2010) Tissue-factor fusion proteins induce occlusion of tumor vessels. Thromb Res 125 (Suppl 2): S143-150.
11. Yokoyama Y, Ramakrishnan S, (2005) Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth. Cancer 104: 321-331.
12. Cao Y, (2004) Antiangiogenic cancer therapy. Semin Cancer Biol 14: 139-145.
13. Cao Y, Cao R, Veitonmaki N, (2002) Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2: 667-681.
14. Gonzalez-Gronow M, Kalfa T, Johnson CE, Gawdi G, Pizzo SV, (2003) The voltage-dependent anion channel is a receptor for plasminogen kringle 5 on human endothelial cells. J Biol Chem 278: 27312-27318.
15. Lu H, Dhanabal M, Volk R, Waterman MJ, Ramchandran R, et al. (1999) Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. Biochem Biophys Res Commun 258: 668-673.
16. Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, et al. (1998) Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 247: 414-419.
17. Davidson DJ, Haskell C, Majest S, Kherzai A, Egan DA, et al. (2005) Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 65: 4663-4672.
18. Bui Nguyen TM, Subramanian IV, Kelekar A, Ramakrishnan S, (2007) Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells. Blood 109: 4793-4802.
19. Soff GA, (2000) Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 19: 97-107.
20. Yang X, Cheng R, Li C, Cai W, Ma JX, et al. (2006) Kringle 5 of human plasminogen suppresses hepatocellular carcinoma growth both in grafted and xenografted mice by anti-angiogenic activity. Cancer Biol Ther 5: 399-405.
21. Ansell PJ, Zhang H, Davidson DJ, Harlan JE, Xue J, et al. (2010) Recombinant kringle 5 from plasminogen antagonises hepatocyte growth factor-mediated signalling. Eur J Cancer 46: 966-973.
22. Yang X, Cai W, Xu Z, Chen J, Li C, et al. (2010) High efficacy and minimal peptide required for the anti-angiogenic and anti-hepatocarcinoma activities of plasminogen K5. J Cell Mol Med 14: 2519-2530.
23. Schmitz V, Raskopf E, Gonzalez-Carmona MA, Vogt A, Kornek M, et al. (2008) Plasminogen derivatives encoding kringles 1-4 and kringles 1-5 exert indirect antiangiogenic and direct antitumoral effects in experimental lung cancer. Cancer Invest 26: 464-470.
24. Li Y, Han W, Zhang Y, Yuan L, Shi X, et al. (2008) Intramuscular electroporation of a plasmid encoding human plasminogen kringle 5 induces growth inhibition of Lewis lung carcinoma in mice. Cancer Biother Radiopharm 23: 332-341.
25. Perri SR, Nalbantoglu J, Annabi B, Koty Z, Lejeune L, et al. (2005) Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res 65: 8359-8365.
26. McFarland BC, Stewart J Jr, Hamza A, Nordal R, Davidson DJ, et al. (2009) Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1. Cancer Res 69: 5537-5545.
27. Bui Nguyen TM, Subramanian IV, Xiao X, Nguyen P, Ramakrishnan S, (2010) Adeno-associated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther 17: 606-615.
28. Jin GH, Ma DY, Wu N, Marikar FM, Jin SZ, et al. (2007) Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect. Int J Cancer 121: 2539-2546.
29. Zou Y, Chen Y, Jiang Y, Gao J, Gu J, (2007) Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor. Cancer Res 67: 7295-7300.
30. Li S, Dong W, Zong Y, Yin W, Jin G, et al. (2007) Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics. Mol Ther 15: 515-523.
31. Sun QM, Cao L, Fang L, Chen C, Dai J, et al. (2005) Expression, purification of human vasostatin120-180 in Escherichia coli, and its anti-angiogenic characterization. Protein Expr Purif 39: 288-295.
32. Crawford AD, Liekens S, Kamuhabwa AR, Maes J, Munck S, et al. (2011) Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants. PLoS One 6: e14694.
33. Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, et al. (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38: 1564-1579.
34. Folkman J, Merler E, Abernathy C, Williams G, (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288.
35. DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, et al. (2004) Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 164: 1131-1139.
36. Browder T, Folkman J, Pirie-Shepherd S, (2000) The hemostatic system as a regulator of angiogenesis. J Biol Chem 275: 1521-1524.
37. Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, et al. (2002) Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277: 47891-47897.
38. Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, et al. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97: 652-659.
39. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, et al. (2010) CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120: 3326-3339.
40. Fontijn D, Duyndam MC, van Berkel MP, Yuana Y, Shapiro LH, et al. (2006) CD13/Aminopeptidase N overexpression by basic fibroblast growth factor mediates enhanced invasiveness of 1F6 human melanoma cells. Br J Cancer 94: 1627-1636.
41. Fujii H, Nakajima M, Saiki I, Yoneda J, Azuma I, et al. (1995) Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin Exp Metastasis. 13: 337-344.
42. Hlatky L, Hahnfeldt P, Folkman J, (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893.
43. Bocci G, Nicolaou KC, Kerbel RS, (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62: 6938-6943.
44. Tan GH, Tian L, Wei YQ, Zhao X, Li J, et al. (2004) Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities. Int J Cancer 112: 701-706.
45. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, et al. (2005) Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 113: 490-498.
46. Pham CD, Roberts TP, van Bruggen N, Melnyk O, Mann J, et al. (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest 16: 225-230.
47. Corti A, Ponzoni M, (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028: 104-112.
48. Jeyapalan JC, Saretzki G, Leake A, Tilby MJ, von Zglinicki T, (2006) Tumour-cell apoptosis after cisplatin treatment is not telomere dependent. Int J Cancer 118: 2727-2734.
49. Polycarpe E, Arnould L, Schmitt E, Duvillard L, Ferrant E, et al. (2004) Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer 111: 131-137.
50. Jiang M, Wei Q, Wang J, Du Q, Yu J, et al. (2006) Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis. Oncogene 25: 4056-4066.